Outlook Therapeutics Inc
OTLK
Get informed when a big investor buys or sells
+ FollowMarket Cap$123.28M
Close$
$-0.10
111.4% downside
Current Fair Value
111.4% downsideOvervalued by 111.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $123.28 Million |
|---|---|
| Enterprise Value | $112.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.79 |
| Beta | 0.78 |
| Outstanding Shares | 81,836,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -67771217.78% |
| Return on Invested Capital | 1256681106.34% |
Valuation & Multiples
| P/E Ratio | -0.75 |
|---|---|
| PEG | 0.75 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$966,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6280▼ 397.23% |
|---|---|
| Total Calls | 246,800▼ 52.22% |
| Total Puts | 155,000▼ 93.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.11%▲ 1.78% |
|---|---|
| Total Invested | $2.21M▼ 79.53% |
| Investors Holding | 59▼ 2.00% |
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon